Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study

Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?

(2018) Lieven Pouillon et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: a Systematic Review and Meta-analysis

(2018) Laurent Peyrin-Biroulet et al.   Clinical Gastroenterology and Hepatology

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease

(2018) Stefan Schreiber et al.   JOURNAL OF GASTROENTEROLOGY

Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

(2018) María Chaparro et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis

(2017) Tal Engel et al.   Journal of Crohns & Colitis

Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study

(2016) D. C. Baumgart et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study

(2016) A. Stallmach et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

(2016) Parambir S Dulai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis

(2016) Shailja C. Shah et al.   Clinical Gastroenterology and Hepatology

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

(2016) Aurelien Amiot et al.   Clinical Gastroenterology and Hepatology

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Review article: anti-adhesion therapies for inflammatory bowel disease

(2014) T. Lobatón et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis

(2014) Christophe Hézode et al.   GASTROENTEROLOGY

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mucosal healing in inflammatory bowel diseases: a systematic review

(2012) Markus F Neurath et al.   GUT

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease

(2010) Gionata Fiorino et al.   Expert Review of Clinical Immunology

Clinical implications of mucosal healing for the management of IBD

(2009) Guillaume Pineton de Chambrun et al.   Nature Reviews Gastroenterology & Hepatology

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT